Chronic myelogenous leukemia diagnostic study of choice

Revision as of 19:15, 11 November 2018 by Badria Munir (talk | contribs) (Overview)
Jump to navigation Jump to search


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Badria Munir M.B.B.S.[2]

Overview

Chronic myelogenous leukemia is diagnosed clinically, based on history and symptoms and is confirmed with karyotyping or FISH. There is no single diagnostic study of choice, different techniques are applied so far to detect philadelphia chromosome, BCR-ABL oncogene,

Diagnostic Study of Choice

Study of choice

Diagnostic results
  • Philadelphia chromosomes
    Philadelphia chromosome
    The following findings on performing PCR is confirmatory for Chronic myelogenous leukemia:
    • The Philadelphia chromosome
    • The BCR-ABL1 fusion gene
    • The BCR-ABL1 fusion mRNA
Sequence of Diagnostic Studies
  • The peripheral blood studies must be performed as a first step when:
  • The patient presented with signs of:
    • Anemia
    • Lecopenia
    • Thrombocytopenia
  • The various investigations must be performed in the following order:[2]
    • Peripheral blood studies
    • Bone marrow biopsy

Name of Diagnostic Criteria:

  • WHO criteria of diagnosing different phases of chronic myeloid leukemia is following: [3][4]
WHO Criteria of diagnosing different phases of CML
CML chronic phase CML accelerated phase CML blast phase
Granulocytosis in the presence of

ph chromosome and/or BCR/ABL

Increasing spleen size and WBC unresponsive to therapy Blasts ≥ 20% in perpheral blood and bone marrow
NO sign of CML accelerated phase Cytogenetic evidence of clonal evolution of

Blasts 10–19% in peripheral blood and/or bone marrow

Extramedullary blast proliferation
Peripheral blood basophils ≥ 20% Large foci or clusters of blasts in the bone marrow biopsy
Persistent thrombocytopenia (< 100 x 109/L)

unrelated to therapy or

Persistent thrombocytosis (> 1000 x 109/L)

unresponsive to therapy

References

  1. Le Gouill S, Talmant P, Milpied N, Daviet A, Ancelot M, Moreau P, Harousseau JL, Bataille R, Avet-Loiseau H (April 2000). "Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia". J. Clin. Oncol. 18 (7): 1533–8. doi:10.1200/JCO.2000.18.7.1533. PMID 10735902.
  2. 2.0 2.1 Melo JV, Myint H, Galton DA, Goldman JM (January 1994). "P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?". Leukemia. 8 (1): 208–11. PMID 8289491.
  3. Empty citation (help)
  4. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (May 2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): 2391–405. doi:10.1182/blood-2016-03-643544. PMID 27069254.

Template:WH Template:WS